Literature DB >> 18160340

C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study.

Eric S Williams1, Sanjiv J Shah, Sadia Ali, Bee Ya Na, Nelson B Schiller, Mary A Whooley.   

Abstract

BACKGROUND: High-sensitivity C-reactive protein (CRP) is an inflammatory marker that predicts coronary heart disease (CHD) and, in recent studies, incident heart failure (HF). Whether the association of inflammation with incident HF is explained by worse baseline left ventricular dysfunction or by underlying CHD is unknown. METHODS AND
RESULTS: Serum CRP was measured in a cohort of 985 outpatients with established CHD from the Heart and Soul Study. During 3 years of follow-up, 15% of the participants with elevated CRP levels (>3 mg/L) were hospitalised for HF, compared with 7% of those with CRP <or= 3 mg/L. In multivariate analysis, elevated CRP was associated with HF after adjustment for traditional risk factors, baseline CHD severity and interim MI (adjusted HR 2.1, 95% CI, 1.2-3.6; p=0.009). However, elevated CRP was no longer associated with HF after further adjustment for the presence of diastolic dysfunction on echocardiography (adjusted HR 1.6, 95% CI, 0.8-3.2; p=0.1).
CONCLUSIONS: Among outpatients with stable CHD, elevated CRP levels predict hospitalisation for heart failure, independent of baseline heart failure, medication use, CHD severity, and subsequent MI events. This relationship appears to be at least partly explained by abnormal diastolic function in patients with elevated CRP levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160340      PMCID: PMC2789557          DOI: 10.1016/j.ejheart.2007.11.003

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  45 in total

1.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 2.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 3.  Coming of age of C-reactive protein: using inflammation markers in cardiology.

Authors:  Edward T H Yeh; James T Willerson
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

4.  Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction.

Authors:  R J Raymond; G J Dehmer; T C Theoharides; E N Deliargyris
Journal:  Am Heart J       Date:  2001-03       Impact factor: 4.749

5.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

6.  C-reactive protein as a predictor of improvement and readmission in heart failure.

Authors:  J L Alonso-Martínez; B Llorente-Diez; M Echegaray-Agara; F Olaz-Preciado; M Urbieta-Echezarreta; C González-Arencibia
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

Review 7.  The treatment targets in acute decompensated heart failure.

Authors:  G C Fonarow
Journal:  Rev Cardiovasc Med       Date:  2001       Impact factor: 2.930

8.  C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study.

Authors:  Mary S Beattie; Michael G Shlipak; Haiying Liu; Warren S Browner; Nelson B Schiller; Mary A Whooley
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

9.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

10.  Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.

Authors:  Ramachandran S Vasan; Lisa M Sullivan; Ronenn Roubenoff; Charles A Dinarello; Tamara Harris; Emelia J Benjamin; Douglas B Sawyer; Daniel Levy; Peter W F Wilson; Ralph B D'Agostino
Journal:  Circulation       Date:  2003-03-25       Impact factor: 29.690

View more
  25 in total

1.  Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Authors:  Arduino A Mangoni; Richard J Woodman; Paraskevi Gaganis; Andrew L Gilbert; Kathleen M Knights
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

2.  Untargeted metabolomic analysis of coronary artery disease patients with diastolic dysfunction show disturbed oxidative pathway.

Authors:  Tamkeen Fatima; Satwat Hashmi; Ayesha Iqbal; Amna Jabbar Siddiqui; Shahid A Sami; Najeeb Basir; Syeda Saira Bokhari; Hasanat Sharif; Syed Ghulam Musharraf
Journal:  Metabolomics       Date:  2019-06-24       Impact factor: 4.290

3.  Left ventricular function and C-reactive protein levels in acute myocardial infarction.

Authors:  Adelaide M Arruda-Olson; Maurice Enriquez-Sarano; Francesca Bursi; Susan A Weston; Allan S Jaffe; Jill M Killian; Véronique L Roger
Journal:  Am J Cardiol       Date:  2010-04-01       Impact factor: 2.778

4.  Determinants of exercise capacity in dilated cardiomyopathy: a prospective, explorative cohort study.

Authors:  Wilhelm Grander; Bernhard Koller; Johannes Schwaiger; Herbert Tilg; Martin W Dünser
Journal:  Wien Klin Wochenschr       Date:  2012-08-10       Impact factor: 1.704

5.  Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study.

Authors:  Andreas Kalogeropoulos; Vasiliki Georgiopoulou; Bruce M Psaty; Nicolas Rodondi; Andrew L Smith; David G Harrison; Yongmei Liu; Udo Hoffmann; Douglas C Bauer; Anne B Newman; Stephen B Kritchevsky; Tamara B Harris; Javed Butler
Journal:  J Am Coll Cardiol       Date:  2010-05-11       Impact factor: 24.094

Review 6.  Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.

Authors:  N Glezeva; J A Baugh
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

7.  Multimarker approach for the prediction of heart failure incidence in the community.

Authors:  Raghava S Velagaleti; Philimon Gona; Martin G Larson; Thomas J Wang; Daniel Levy; Emelia J Benjamin; Jacob Selhub; Paul F Jacques; James B Meigs; Geoffrey H Tofler; Ramachandran S Vasan
Journal:  Circulation       Date:  2010-10-11       Impact factor: 29.690

8.  Serum albumin concentration and heart failure risk The Health, Aging, and Body Composition Study.

Authors:  Deepa M Gopal; Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Wilson W H Tang; Amanda Methvin; Andrew L Smith; Douglas C Bauer; Anne B Newman; Lauren Kim; Tamara B Harris; Stephen B Kritchevsky; Javed Butler
Journal:  Am Heart J       Date:  2010-08       Impact factor: 4.749

9.  Impact of HIV infection on diastolic function and left ventricular mass.

Authors:  Priscilla Y Hsue; Peter W Hunt; Jennifer E Ho; Husam H Farah; Amanda Schnell; Rebecca Hoh; Jeffrey N Martin; Steven G Deeks; Ann F Bolger
Journal:  Circ Heart Fail       Date:  2009-11-20       Impact factor: 8.790

Review 10.  Pathophysiological mechanism and therapeutic role of S100 proteins in cardiac failure: a systematic review.

Authors:  Egidio Imbalzano; Giuseppe Mandraffino; Marco Casciaro; Sebastiano Quartuccio; Antonino Saitta; Sebastiano Gangemi
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.